Log inSign up
AAOIFI No. 21 screening

Is IMDX halal?

Insight Molecular Diagnostics I

Halal

Insight Molecular Diagnostics I passed every check under AAOIFI Shariah standard No. 21: no prohibited business activity, and all three financial ratios are within limits.

Checked: 14 October 2026

Exchange

NASDAQ

Price

3.01

Day

-1.63%

Market cap

$98.7M

Industry

Diagnostics & Research

Sector

Healthcare

What the company does

Insight Molecular Diagnostics (formerly Oncocyte) makes blood tests for transplant-organ rejection (GraftAssure) and cancer diagnostics (DetermaIO). Its money comes from test and reagent sales, still small.

What was checked

The AAOIFI standard has four steps: business activity first, then three financial ratios. Fail one and the stock is not halal.

  • Business activity

    No prohibited activity

  • Interest-bearing debt / market cap

    limit 30%

    Interest-bearing debt $946K ÷ 36-month average market cap $85.90M = 1.1%

    1.1%

    Pass

  • Cash & investments / market cap

    limit 30%

    Cash + interest-bearing securities $17.76M ÷ 36-month average market cap $85.90M = 20.7%

    20.7%

    Pass

  • Non-compliant income / total revenue

    limit 5%

    —

    No data

Figures from the company's filings (2026-06-30), USD. Market cap is a 36-month average (the S&P Shariah index approach), so a one-day price move does not flip the verdict. Today's market cap: $98.66M.

For information (AAOIFI 3/1 note): cash + receivables are 61.0% of total assets (2026-06-30). AAOIFI recommends tangible assets of at least one third — this figure does not affect the verdict, and other major screeners do not apply it either.

In the lists

In the S&P 500
Not in the S&P 500
Among halal stocks
0.00% · #1192 of 1454

Halal stocks in the same industry

The largest halal stocks in Diagnostics & Research — for comparison.

Related articles

Halal is the first question. The second: when to enter?

Our scanner watches 1454 halal stocks around the clock and fires a signal with entry, TP and SL when a technical setup completes. The full signal history — with outcomes — is public.

This is neither investment advice nor a fatwa. Screening is based on public financial statements and AAOIFI standard No. 21; data may lag. For a personal decision consult your own scholar.

Earnings historyIMDX's next report date, EPS estimate vs actual for recent quarters and the post-earnings price move.View earnings →